Dr. Porteus is an Associate Clinical Professor and attends at the Lucille Packard Children’s Hospital where he takes care of pediatric patients undergoing hematopoietic stem cell transplantation. He completed his combined MD, PhD at Stanford Medical School, and residency in Pediatrics at Boston Children’s Hospital. For his fellowship and postdoctoral research, he applied homologous recombination as a strategy to correct disease causing mutations in stem cells as definitive and curative therapy for children with genetic diseases of the blood, particularly sickle cell disease. His research program continues to focus on developing genome editing by homologous recombination as curative therapy for children with genetic diseases but also has interests in the clonal dynamics of heterogeneous populations and the use of genome editing to better understand musculoskeletal diseases.
Keith Wailoo, PhD is Henry Putnam University Professor of History and Public Affairs. He is jointly appointed in the Department of History and in the Princeton School of Public and International Affairs. He is former Vice Dean of the School of Public and International Affairs, former Chair of History, and current President of the American Association for the History of Medicine (2020-2022). His research straddles history and health policy, touching on drugs and drug policy, on the politics of race and health, on the interplay of identity, ethnicity, gender, and medicine, and on controversies in genetics and society. His next book, to be published in 2021, is Pushing Cool: Big Tobacco, Racial Marketing, and the Untold Story of the Menthol Cigarette (University of Chicago Press).
Holly Fernandez Lynch, JD, MBE, is the John Russell Dickson, MD Presidential Assistant Professor of Medical Ethics in the Department of Medical Ethics and Health Policy at the Perelman School of Medicine, University of Pennsylvania. A lawyer and bioethicist by training, her scholarly work focuses on the ethics and regulation of research with human subjects and related issues, including access to investigational therapies outside clinical trials before they have been approved by the FDA. She is the founder and co-chair of the Consortium to Advance Effective Research Ethics Oversight (AEREO), which aims to understand, evaluate, and improve IRB quality and effectiveness. During the COVID-19 pandemic, she has focused on FDA policy, drug and vaccine development, ethical conduct of research and allocation of scarce investigational products.
Jason A. Delborne is Professor of Science, Policy, and Society and University Faculty Scholar at North Carolina State University, with appoints in the Department of Forestry and Environmental Resources in the College of Natural Resources and the Genetic Engineering and Society Center. He teaches and conducts research at the intersection of environmental policy, biotechnology, and public engagement, using qualitative research methodologies to explore how policymakers, stakeholders and members of the public interface with emerging biotechnologies designed for environmental benefit. Delborne was twice appointed to expert committees of the National Academies of Sciences, Engineering, and Medicine (NASEM), which published Gene Drives on the Horizon (2016) and Forest Health and Biotechnology (2019). Recent projects have focused on the genetically engineered chestnut tree, a gene drive mouse for biodiversity conservation, and the management of free ranging cats in National Parks.